| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 754 | 831 | 871 | 823 | 819 | 1,299 | 795 | 803 | 707 | 888 | 834 | 785 | 764 | 964 | 838 | 2,132 | 776 | 939 | 826 | 826 | 815 | 985 | 833 | 962 | 850 | 1,050 | 985 | 1,015 | 849 |
| Expenses | 608 | 663 | 688 | 588 | 623 | 688 | 1,408 | 602 | 535 | 739 | 611 | 707 | 586 | 678 | 636 | 634 | 596 | 660 | 585 | 618 | 618 | 668 | 751 | 673 | 584 | 689 | 658 | 641 | 554 |
| EBITDA | 145 | 168 | 183 | 236 | 196 | 611 | -613 | 201 | 172 | 150 | 223 | 78 | 178 | 286 | 202 | 1,497 | 180 | 279 | 241 | 208 | 198 | 318 | 83 | 290 | 266 | 361 | 327 | 374 | 295 |
| Operating Profit % | 17 % | 19 % | 17 % | 22 % | 21 % | 22 % | -81 % | 22 % | 18 % | 16 % | 23 % | 5 % | 18 % | 27 % | 22 % | 22 % | 20 % | 28 % | 27 % | 22 % | 19 % | 30 % | 7 % | 28 % | 28 % | 32 % | 31 % | 34 % | 31 % |
| Depreciation | 11 | 12 | 12 | 14 | 19 | 23 | 18 | 23 | 22 | 22 | 18 | 18 | 18 | 17 | 18 | 15 | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Profit Before Tax | 134 | 157 | 171 | 222 | 176 | 587 | -634 | 177 | 149 | 127 | 204 | 60 | 160 | 268 | 184 | 1,482 | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 |
| Tax | 50 | 56 | 57 | 75 | 63 | 85 | 27 | 39 | 38 | 51 | 48 | 45 | 39 | 64 | 34 | 263 | 44 | 69 | 60 | 57 | 49 | 82 | 20 | 76 | 67 | 91 | 78 | 96 | 74 |
| Net Profit | 84 | 101 | 114 | 147 | 114 | 503 | -661 | 138 | 111 | 77 | 157 | 14 | 121 | 204 | 150 | 1,219 | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 195 | 182 | 253 | 230 | 263 | 205 |
| EPS in ₹ | 9.93 | 5.95 | 6.71 | 8.67 | 6.70 | 29.68 | -39.03 | 8.15 | 6.54 | 4.51 | 10.26 | 0.85 | 7.14 | 12.06 | 8.87 | 71.96 | 7.04 | 11.42 | 9.71 | 7.41 | 7.04 | 12.84 | 9.89 | 11.37 | 10.76 | 14.67 | 13.57 | 15.52 | 12.10 |
GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals
2,774.00
-89.80
(-3.14%)
Market Cap
46,993.23 Cr
EPS
54.76
PE Ratio
51.23
Dividend Yield
1.89 %
Industry
Healthcare52 Week High
3,515.70
52 Week Low
1,921.00
PB Ratio
24.86
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
GlaxoSmithKline Pharma Launches Two Oncology Drugs in IndiaAug 25, 2025
GlaxoSmithKline Pharma has entered India's oncology market by introducing two cancer treatment drugs - Jemperli and Zejula. Both medications are designed to provide targeted treatments specifically for gynecological cancers.
GlaxoSmithKline Pharmaceuticals Limited reported flat revenue growth for Q1 FY26, impacted by supply constraints from a CMO fire incident that reduced growth by 2% and muted performance in dermatology and anti-infective segments. Despite challenging topline performance, the company improved EBITDA margins to 31.2% (290 basis points improvement) and achieved 12.7% PAT growth. The vaccine business grew 8.6% while general medicines declined 2%. The company is launching two oncology drugs - Zejula for ovarian cancer and Jemperli for endometrial cancer - targeting approximately 5,000 and 1,000 eligible patients respectively. Management maintains confidence in achieving double-digit growth ambitions, supported by new growth platforms including Shingrix vaccine (selling 9,000-10,000 doses monthly), specialty products like Trelegy Ellipta and Nucala, and the upcoming oncology portfolio. The company operates with over 2,000 medical representatives and has expanded digital reach to 4.6 lakh healthcare practitioners.
GlaxoSmithKline Pharmaceuticals Reports Q1 FY26 Results with Margin Expansion Despite Revenue Decline
Aug 01, 2025
Aug 01, 2025GlaxoSmithKline Pharmaceuticals Limited reported quarterly results showing revenue of ₹805 crores, declining 0.8% year-over-year. However, the company demonstrated strong profitability improvements with EBITDA of ₹205 crores at 25.6% margin (up 290 basis points) and PAT of ₹251 crores at 31.2% margin (also up 290 basis points), representing growth of 9.3% and 12.7% respectively. EPS increased 13% to ₹12.08. The General Medicine segment faced challenges due to softer seasonality and competitive pressures, while the Specialty segment drove growth led by respiratory focus. The company's pediatric vaccines portfolio showed growth driven by Boostrix, Varilrix, and Havrix brands. GSK is launching two oncology products - Jemperli and Zejula - targeting gynecological cancers. The company maintained healthy cash flow conversion at approximately 100% and improved field productivity by 1%. Key promoted brands continued outperforming in their represented markets while gaining market share.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,616.60 | #1 3,87,876.49 | 33.67 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 49.00 | |
6,026.50 | 1,59,984.64 | 69.22 | 9,712.00 | 18.67 | 2,191 | 26.74 | 39.47 | |
1,574.60 | 1,27,181.67 | 23.38 | 28,409.50 | 7.12 | 5,291 | 9.88 | 52.08 | |
3,566.20 | 1,20,696.41 | 60.00 | 11,539.40 | 6.99 | 1,911 | 19.91 | 48.74 | |
1,316.70 | 1,09,887.98 | #1 19.15 | 33,741.20 | 16.73 | 5,725 | 1.26 | 60.35 | |
2,579.60 | 1,06,467.51 | 56.70 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 58.41 | |
1,044.75 | 1,05,126.30 | 22.52 | 23,511.00 | 18.55 | 4,615 | 2.60 | 68.18 | |
2,043.40 | 93,321.15 | 24.55 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 59.44 | |
30,980.00 | 65,830.34 | 45.32 | 6,684.70 | 9.64 | 1,414 | 11.55 | 39.39 | |
5,448.00 | 65,139.01 | 28.38 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.73 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
8.91 %
Net Income Growth
57.22 %
Cash Flow Change
121.62 %
ROE
43.24 %
ROCE
42.20 %
EBITDA Margin (Avg.)
17.79 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Fixed Assets | 123 | 210 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 |
| Current Assets | 2,587 | 2,174 | 1,674 | 2,186 | 2,010 | 1,775 | 2,203 | 3,708 | 2,494 | 2,798 | 3,410 |
| Capital Work in Progress | 115 | 268 | 606 | 923 | 1,003 | 120 | 13 | 31 | 20 | 14 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Current Liabilities | 1,107 | 579 | 720 | 1,600 | 1,454 | 1,024 | 1,355 | 1,698 | 1,326 | 1,525 | 1,905 |
| Non Current Liabilities | 280 | 292 | 277 | 290 | 317 | 291 | 282 | 272 | 259 | 254 | 252 |
| Total Equity | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,478 | 2,663 | 1,741 | 1,778 | 1,951 |
| Reserve & Surplus | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 |
| Share Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 |
| Investing Activities | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 |
| Operating Activities | 338 | 139 | 234 | 473 | 410 | 491 | 578 | 811 | 484 | 582 | 1,290 |
| Financing Activities | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.48 % | 4.02 % | 4.36 % | 4.50 % | 4.52 % | 4.89 % |
| DIIs | 5.31 % | 5.51 % | 5.50 % | 5.61 % | 5.61 % | 4.08 % | 10.45 % | 10.28 % | 10.30 % | 10.23 % | 10.01 % | 8.53 % | 7.90 % | 7.50 % | 7.34 % | 7.30 % | 7.79 % | 7.70 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 11.02 % | 10.86 % | 10.83 % | 10.67 % | 10.41 % | 10.41 % | 10.40 % | 10.56 % | 10.54 % | 10.57 % | 10.62 % | 11.08 % | 11.27 % | 11.15 % | 10.97 % | 10.96 % | 10.60 % | 10.32 % |
| Others | 8.67 % | 8.62 % | 8.67 % | 8.73 % | 8.98 % | 10.51 % | 4.15 % | 4.16 % | 4.16 % | 4.20 % | 4.37 % | 5.38 % | 2.35 % | 2.33 % | 2.33 % | 2.23 % | 2.09 % | 2.09 % |
| No of Share Holders | 1,19,951 | 1,20,476 | 1,21,445 | 1,23,480 | 1,10,141 | 1,12,964 | 1,16,651 | 1,20,127 | 1,20,415 | 1,19,032 | 1,15,266 | 1,14,663 | 1,18,994 | 1,18,515 | 1,19,228 | 1,19,625 | 1,21,885 | 1,23,629 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 30 | 35 | 20 | 40 | 30 | 90 | 32 | 32 | 54 |
| Dividend Yield (%) | 0.00 | 2.87 | 2.7 | 1.59 | 2.78 | 1.8 | 7.05 | 1.64 | 1.11 | 1.95 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Sept 2018 |  Bonus | 1:1 | 11 Sept 2018 | 1,726.60 | 1,724.70 |
| 20 Jul 2021 |  Dividend | ₹ 30.00 /share | 19 Jul 2021 | 1,518.15 | 1,607.55 |
| 08 Jul 2022 | Dividend | ₹ 60.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 08 Jul 2022 | Dividend | ₹ 30.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 26 Jul 2022 |  Annual General Meeting | NA | 26 Jul 2022 | 1,493.30 | 1,493.85 |
| 30 Jun 2023 | Dividend | ₹ 32.00 /share | 30 Jun 2023 | 1,289.55 | 1,438.20 |
| 31 May 2024 | Dividend | ₹ 32.00 /share | 31 May 2024 | 2,023.85 | 2,593.00 |
| 28 Jun 2024 | Annual General Meeting | NA | 28 Jun 2024 | 2,023.85 | 2,677.55 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 2,630.85 | 2,644.65 |
| 07 Nov 2024 | Dividend | ₹ 12.00 /share | 07 Nov 2024 | 2,644.65 | 2,632.20 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 2,077.20 | 1,998.80 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 2,928.60 | 2,721.25 |
| 30 May 2025 | Dividend | ₹ 42.00 /share | 30 May 2025 | 2,721.25 | 3,263.40 |
| 27 Jun 2025 | Annual General Meeting | NA | 27 Jun 2025 | 2,721.25 | 3,301.90 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 3,262.85 | 3,158.15 |
Announcements
Disclosure Under Regulation 305 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 25, 2025
Aug 25, 2025Disclosure Under Regulation 30Aug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Disclosure Under Regulation 30Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2025
Aug 04, 2025Rumour verification - Regulation 30(11)Aug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 02, 2025
Aug 02, 2025Clarification sought from GlaxoSmithKline Pharmaceuticals LtdAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 01, 2025
Aug 01, 2025Board Meeting Outcome for Outcome Of MeetingAug 01, 2025
Aug 01, 2025Quarter Ended 30Th June 2025Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Jul 09, 2025Board Meeting Intimation for Board Meeting Intimation
Jul 04, 2025
Jul 04, 2025Outcome Of AGMJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Disclosure Under Regulation 30Jun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Analyst MeetJun 20, 2025
Jun 20, 2025Disclosure Under Regulation 30Jun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025Letter To Shareholders For Annual Report LinkJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025100Th Annual General Meeting On 27Th June 2025Jun 03, 2025
Jun 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 03, 2025
Jun 03, 2025Reg. 34 (1) Annual Report.Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 02, 2025
Jun 02, 2025Disclosure Under Regulation 30May 16, 2025
May 16, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
May 13, 2025Appointment Of Parikh & Associates As Secretarial Auditor Of The Company
May 13, 2025
May 13, 2025100Th Annual General Meeting On 27Th June 2025May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
May 13, 2025Record Date For Final Dividend 30Th May 2025May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
May 13, 2025Corporate Action-Board approves DividendMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Outcome Of MeetingMay 13, 2025
May 13, 2025Technical Indicators
RSI(14)
Neutral 44.11
ATR(14)
Volatile 84.97
STOCH(9,6)
Neutral 62.28
STOCH RSI(14)
Overbought 80.39
MACD(12,26)
Bullish 17.08
ADX(14)
Weak Trend 15.90
UO(9)
Bearish 53.66
ROC(12)
Downtrend And Accelerating -0.55
WillR(14)
Neutral -59.65
Mutual Fund Holdings
Sundaram Multi-Factor Fund Direct-Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Aditya Birla Sun Life Large & Mid Cap Fund Direct -Growth 
SBI Quant Fund Direct-Growth 
Samco Flexi Cap Fund Direct - Growth 
Edelweiss Business Cycle Fund Direct-Growth 
Baroda BNP Paribas Midcap Fund Direct-Growth 
Mahindra Manulife Small Cap Fund Direct - Growth 
Helios Mid Cap Fund Direct-Growth 
DSP Quant Fund Direct - Growth 
Motilal Oswal Quant Fund Direct-Growth 
JM Midcap Fund Direct - Growth 
Nippon India Active Momentum Fund Direct-Growth 
360 ONE Quant Fund Direct - Growth About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Website
Chairperson NameRenu S Karnad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
